The S&BC team has been asked to help determine whether the drug should be
*Swap = Trading the drug in exchange with another company’s drug
In two of the three options Bayer keeps the drug while one is selling it, which factors would you assess whether to keep the drug or to sell it?
Determine EBITDA in 2020 for launch alone option.
Please compare the three proposed options (launched alone; co-marketed with a partner and solid, licensed out or swapped) based on the following factors
and make a final recommendation as to what Bayer should do.